Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Erythromycin Tablets USP, 250 mg and 500 mg (USRLD: Erythromycin Tablets USP, 250 mg and 500 mg).
Erythromycin tablets, USP is an antibacterial product and is used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire's disease and pertussis. The drug will be manufactured at the group's formulation manufacturing facility in SEZ, Ahmedabad (India).
Erythromycin Tablets USP, 250 mg and 500mg had annual sales of USD 23mn in the United States (IQVIA MAT July 2023).
The group now has 379 approvals and has so far filed over 444* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 625.45 as compared to the previous close of Rs. 628.15. The total number of shares traded during the day was 34461 in over 1958 trades.
The stock hit an intraday high of Rs. 633.90 and intraday low of 622.05. The net turnover during the day was Rs. 21604748.00.
(*as of 30th June 2023)